| Excerpt | Reference |
|---|
| "Chronic inflammatory demyelinating polyradiculoneuropathy is an autoimmune peripheral neuropathy and would be expected to benefit from corticosteroids." | ( Hughes, RA; Mehndiratta, MM, 2001) |
| "Chronic inflammatory demyelinating polyradiculoneuropathy is a peripheral neuropathy caused by peripheral nerve inflammation probably due to autoimmunity and would be expected to benefit from corticosteroids." | ( Hughes, RA; Mehndiratta, MM, 2002) |
| "Chronic inflammatory demyelinating polyradiculoneuropathy is a disease causing progressive or relapsing and remitting weakness and numbness." | ( Hughes, RA; Swan, AV; van Doorn, PA, 2003) |
| "Chronic inflammatory demyelinating polyradiculoneuropathy is an inflammatory disorder of nerve that usually presents with slowly progressive weakness and sensory loss and areflexia." | ( Kissel, JT, 2003) |
| "Chronic inflammatory demyelinating polyradiculoneuropathy is a disease causing progressive or relapsing and remitting weakness and numbness." | ( Hughes, RA; Swan, AV; van Doorn, PA, 2004) |
| "In conclusion, CIDP is a clinically heterogeneous disorder." | ( Anyfanti, C; Ioannou, M; Kaponi, A; Pandis, D; Rentzos, M; Vassilopoulos, D, 2007) |
| "Chronic inflammatory demyelinating polyradiculoneuropathy is a disease causing progressive or relapsing and remitting weakness and numbness." | ( Hughes, RA; Mahdi-Rogers, M; Swan, AV; van Doorn, PA, 2010) |
| "Childhood CIDP is rare." | ( Ceulemans, BP; Cras, P; Jadoul, C; Mercelis, R; Riekhoff, AG, 2012) |
| "CIDP is a rare and polymorphic disorder with a variety of concurrent pathologies." | ( Baradai, N; Bedoui, I; Kacem, A; Mansour, M; Mrissa, R; Rachdi, A, 2022) |
| Excerpt | Reference |
|---|
| "Most patients with CIDP and those with MMN need long-term treatment." | ( Garssen, MP; Van Doorn, PA, 2002) |
| "Patients with CIDP examined prior to immunomodulatory treatment had elevated CSF levels of MIP-3beta (a chemoattractant for mature dendritic cells, naïve and recently activated T cells) and IP-10." | ( Jin, JP; Link, H; Pashenkov, M; Press, R, 2003) |
| "Treatment of patients with CIDP using high-dose intermittent IVMP results in improved strength equal to that with IVIg and oral prednisone." | ( Al-Lozi, M; Lopate, G; Pestronk, A, 2005) |
| "Because of the propensity for relapse, CIDP requires maintenance therapy after the initial response to treatment." | ( Hirata, K; Odaka, M; Susuki, K; Tatsumoto, M; Yuki, N, 2005) |
| "A patient with CIDP was treated with oral prednisolone and cyclophosphamide pulse therapy but required repeated plasma exchange and intravenous immunoglobulin (IVIg)." | ( Hirata, K; Odaka, M; Susuki, K; Tatsumoto, M; Yuki, N, 2005) |
| "117 patients with CIDP who met specific neurophysiological inflammatory neuropathy cause and treatment (INCAT) criteria participated in a randomised, double-blind, placebo-controlled, response-conditional crossover trial." | ( Bril, V; Dalakas, MC; Deng, C; Donofrio, P; Hanna, K; Hartung, HP; Hughes, RA; Latov, N; Merkies, IS; van Doorn, PA, 2008) |
| "We report a patient with chronic inflammatory demyelinating polyradiculoneuropathy and progressive resistance to standard treatment who showed a striking response to methotrexate, 20 mg/week." | ( Díaz-Manera, J; Gallardo, E; Illa, I; Rojas-García, R, 2009) |
| "Patients with a pure motor CIDP may deteriorate after corticosteroid treatment." | ( Kuitwaard, K; van Doorn, PA, 2009) |
| "Recent trials for other agents for CIDP treatment have not proved as promising, with a large study of methotrexate failing to show significant benefit." | ( Dyck, PJ; Tracy, JA, 2010) |
| "We report 3 cases of CIDP in children with good outcome after MP pulse therapy." | ( Boulaajaj, FZ; El Moutawakkil, B; Rafai, MA; Sekkat, Z; Slassi, I, 2010) |
| "First-line treatment options for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are corticosteroids, intravenous immunoglobulin, and plasma exchange." | ( Benzing, T; Burghaus, L; Dohmen, C; Fassbender, C; Fink, GR; Frischmuth, N; Galldiks, N; Haupt, WF; Hollinger, P; Klingel, R; Leebmann, J; Nazli, N; Pollok, M; Teschner, S, 2011) |
| "The diagnosis of CIDP had been retained on clinical and electrophysiological grounds for all patients, but we observed no improvement after immunomodulatory treatment." | ( Boukhris, S; Diallo, L; Magy, L; Mathis, S; Vallat, JM, 2012) |
| "Treatment of CIDP with IVIg for 6 months was less frequently discontinued because of inefficacy, adverse events, or intolerance than was treatment with intravenous methylprednisolone." | ( Antonini, G; Beghi, E; Cavaletti, G; Cocito, D; Fazio, R; Francia, A; Gallia, F; Giannini, F; Jann, S; Macchia, R; Messina, P; Nobile-Orazio, E; Pareyson, D; Sabatelli, M; Santoro, L; Schenone, A; Tamburin, S; Uncini, A, 2012) |
| "Peripheral blood from 48 CIDP patients (21 untreated who were either treatment naïve or without treatment during the last 3 months, 17 IVIG and 10 GS treatment) and from 12 age-matched controls was evaluated using flow cytometric analysis." | ( Klehmet, J; Meisel, A; Meisel, C; Staudt, M; Ulm, L; Unterwalder, N, 2015) |
| "Low post-treatment IgG dimer levels in CIDP patients were associated with clinical worsening during IVIg treatment." | ( Bobylev, I; Lehmann, HC; Ritter, C, 2015) |
| "Recently, the number of case reports of CIDP with CNS lesions has gradually been increasing, while the information about the diagnosis and the treatment responses are not enough." | ( Kira, JI; Koda, T; Mochizuki, H; Nakatsuji, Y; Ogata, H; Shimizu, M, 2017) |
| "He was finally diagnosed with CIDP and administration of high dose intravenous methylprednisolone relieved his chest and back pain within a few days." | ( Murase, N; Nakamura, M; Ohtani, R; Oka, N; Yasuda, K, 2018) |
| "Conversely, typical CIDP sera decreased claudin-5 mRNA/protein levels and TEER values in HPnMECs; however, pretreatment with fingolimod-phosphate inhibited the effects of the typical CIDP sera." | ( Kanda, T; Koga, M; Maeda, T; Nishihara, H; Okamoto, N; Sano, Y; Shimizu, F; Takeshita, Y; Ueno, M, 2018) |
| "Childhood chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare condition, and the optimal treatment strategy is not well established, especially in refractory cases." | ( Chae, JH; Choi, J; Choi, SA; Hwang, H; Kim, H; Kim, KJ; Kim, SY; Kim, W; Lim, BC; Shim, YK, 2019) |
| "Typical treatment for CIDP includes corticosteroids, intravenous immunoglobulin (IVIG), and plasma exchange." | ( Patel, AS; Sehdev, A; Snook, RJ, 2019) |
| "We describe two cases of CIDP secondary to treatment with combined ipilimumab and nivolumab in patients with metastatic melanoma that were successfully treated with prednisone and IVIG." | ( Patel, AS; Sehdev, A; Snook, RJ, 2019) |
| "He was diagnosed with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) on the basis of nerve conduction studies and a sural nerve biopsy; however, he was inadequately treated and his weakness had progressed." | ( Ishiguchi, E; Kanda, T; Kawai, M; Maeda, T; Ogasawara, JI; Omoto, M, 2020) |
| "Patients with CIDP respond adequately to steroid therapy and intravenous immunoglobulin (IVIG)." | ( Galnares-Olalde, JA; López-Hernández, JC; Mercado-Pompa, A; Pérez-Torres, T; Vargas-Cañas, ES, 2021) |
| "In addition, patients with typical CIDP were divided into two groups according to the first-line treatment modalities (group 1: IVIg only, group 2: IVIg + steroid)." | ( Acar Arslan, E; Aksoy, A; Aksoy, E; Aliyeva, N; Ayanoğlu, M; Bektaş, Ö; Bodur, M; Canpolat, M; Çobanoğulları Direk, M; Gençpınar, P; Güleç, A; Gümüş, H; Gürkaş, E; Hız Kurul, S; Kanmaz, S; Keskin Yılmaz, S; Kızılırmak, AB; Kömür, M; Okuyaz, Ç; Olgaç Dündar, N; Öz Tuncer, G; Öztoprak, Ü; Öztürk, S; Per, H; Sarıkaya Uzan, G; Teber, S; Tekgül, H; Tosun, A; Ünalp, A; Ünay, B; Vural, A; Yıldırım, Ç; Yılmaz, Ü; Yiş, U; Yousefi, M; Yüksel, D, 2023) |
| "fSCIG 10% more effectively prevented CIDP relapse than placebo, supporting its potential use as maintenance CIDP treatment." | ( Andersen, H; Anderson-Smits, C; Ay, H; Bar, M; Brannagan, TH; Bril, V; Chroni, E; Duff, K; Greco, E; Hadden, RDM; Hasan, S; Latov, N; Levine, T; Li, Z; Pasnoor, M; Rejdak, K; Rivero, A; Sacconi, S; Souayah, N; Yel, L, 2023) |
| "We report a case of SLE presenting with CIDP successfully treated." | ( Bello-Gualtero, JM; Calixto, OJ; Guzman Molano, LF; Meneses-Toro, MA; Poveda, S; Romero-Sánchez, C; Vera-Parra, EC, 2023) |